ALZAMEND NEURO INC (ALZN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.66-2.35%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ALZN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers
ALZN — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar…
Dated 2026-08-03
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 20, 2026, the Company notified Nasdaq that it was not in compliance with the majority independent board standard under Nasdaq Listing Rule 5605(b)(1) which requires listed companies to have a majority of the board of directors be comprised of “Independent Directors” (as defined in Nasdaq Listing Rule 5605(a)(2)) (the “ Majority Independent Board Standard ”). As previously disclosed by…
Why it matters: This capital raise is crucial for funding operations and managing cash burn.
Supportive ifA press release confirming the sale of all 25,000 shares of Series D stock.
Worry ifAnnouncement of delays or failure to complete the sale.
Why it matters: Raising money helps keep operations running. It also helps cover losses.
Supportive ifThere is news about more stock offerings. The current Series D offering may finish soon.
Worry ifNot getting more funding or delays in raising money are concerns.
Why it matters: If healthcare sector revenue growth speeds up, it may help ALZN's performance. This could signal a better environment for growth.
Supportive ifHealthcare sector revenue growth exceeds 10% year over year.
Worry ifHealthcare sector revenue growth remains below 5% year over year.
Why it matters: Management's capital direction affects funding for projects. A shift could impact Alzamend's growth plans.
Watch forManagement shares a new funding plan that is better for capital.
Also watch forManagement sticks to a plan that is not good for capital. This limits growth.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$226 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $667 loss on $10,000 · 6.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,727 loss on $10,000 · 67.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: A drop in revenue growth could signal a weakening position in the healthcare sector. This could affect investor confidence.
Worry ifRevenue growth reported below the median for the sector.
Less concerning ifRevenue growth remains above the median for the sector.
Why it matters: The company faces a potential delisting due to compliance issues. Updates will show progress.
Worry ifA public statement shows that the company meets the independent board standard.
Less concerning ifNasdaq sent more warnings about not following the rules.
Why it matters: The sale can give needed money to support operations and cut cash burn.
Supportive ifThe company announced a successful Series D preferred stock sale. They received the funds.
Worry ifNot completing the sale or bad news about the agreement.
Why it matters: Updates on compliance could affect the company's listing status. This is crucial for investor confidence.
Worry ifA successful fix of the independent board standard by the next earnings call.
Less concerning ifMore notices of non-compliance or threats of delisting from Nasdaq.
Why it matters: Growing losses show bigger financial problems. This hurts investor trust and future funding.
Worry ifOperating losses exceed $2.87M in Q3.
Less concerning ifOperating losses drop or stay below $2.87M.